Four new product launches in prostate cancer over the next 10 years, including Medivation’s androgen receptor inhibitor MDV3100 and Takeda’s 17, 20 lyase inhibitor TAK-700 will counter generic erosion. In addition Increasing use of Zytiga (abiraterone; Johnson&Johnson) and Jevtana (cabazitaxel;Sanofi) will boost market value from $1.7bn in 2011 to $4.3bn by 2020.
Features and benefits
• Access Datamonitor’s patient based prostate cancer market forecast for the seven major markets, with transparent methodology and clear assumptions.
• See how each new product launch will impact the market, and where the strongest competition lies.
• Gain insight into prostate cancer market dynamics, and see where market potential remains.
No. of Pages: 58
Price: Single User License – US$11400 Corporate User License – US$28500
Datamonitor forecasts sales for prostate cancer to reach $1.7bn in 2011 in the seven major markets, growing to $4.3bn by 2020, representing a positive 2011-2020 CAGR of 8%. However, Datamonitor’s survey of 124 medical oncologists and urologists suggests that high levels of unmet need remain in preventing the emergence of castration resistance.
Datamonitor estimates that in 2011 the antihormonal class of drugs dominated the prostate cancer market with 63% market share, owing to wide use in both clinically localized and advanced disease. Zytiga is set to become market leader with market share peaking at 18% before patent expiry.
Sales of cytotoxic and immunotherapeutic drugs including Jevtana (cabazitaxel; Sanofi) and Provenge (sipuleucel-T; Dendreon) constituted 30% of market sales across the seven major markets in 2011. This will decrease to 28% over the forecast period owing to Jevtana’s patent expiry and greater use of alternative therapies with lower toxicity.
Major points covered in Table of Contents of this report include:
• OVERVIEW
• EXECUTIVE SUMMARY
• MARKET DEFINITION
• MARKET OVERVIEW AND CONTEXT
• PRODUCT FORECASTS
• BIBLIOGRAPHY
• APPENDIX
• List Of Tables
• List Of Figures
Explore Comprehensive list of Tables & Figures available in the report @ http://www.reportsnreports.com/reports/144315-market-and-product-forecasts-prostate-cancer.html
Features and benefits
• Access Datamonitor’s patient based prostate cancer market forecast for the seven major markets, with transparent methodology and clear assumptions.
• See how each new product launch will impact the market, and where the strongest competition lies.
• Gain insight into prostate cancer market dynamics, and see where market potential remains.
Prostate Cancer Market
Published: December 2011No. of Pages: 58
Price: Single User License – US$11400 Corporate User License – US$28500
Datamonitor estimates that in 2011 the antihormonal class of drugs dominated the prostate cancer market with 63% market share, owing to wide use in both clinically localized and advanced disease. Zytiga is set to become market leader with market share peaking at 18% before patent expiry.
Sales of cytotoxic and immunotherapeutic drugs including Jevtana (cabazitaxel; Sanofi) and Provenge (sipuleucel-T; Dendreon) constituted 30% of market sales across the seven major markets in 2011. This will decrease to 28% over the forecast period owing to Jevtana’s patent expiry and greater use of alternative therapies with lower toxicity.
Major points covered in Table of Contents of this report include:
• OVERVIEW
• EXECUTIVE SUMMARY
• MARKET DEFINITION
• MARKET OVERVIEW AND CONTEXT
• PRODUCT FORECASTS
• BIBLIOGRAPHY
• APPENDIX
• List Of Tables
• List Of Figures
Explore Comprehensive list of Tables & Figures available in the report @ http://www.reportsnreports.com/reports/144315-market-and-product-forecasts-prostate-cancer.html
No comments:
Post a Comment